Attendance	
Call to Order: 5:05pm	
Approval of Minutes	
Discussion	Action
Discussion	Action
August minutes – votes	11 Votes - accepted
Old Business:	
None	
	No Discussion
New Business:	
None	

New Products			
	Decision		
Drug Name	All Lines of Business	Discussion	Vote Count
	(Where applicable)		
Zynteglo (betibeglogene	☐ Must Add		Must Add- 0
autotemcel) IV		None	May Add- 11
	☐ Do Not Add		Do Not Add- 0
Skysona (elivaldogene autotemcel)	☐ Must Add	: do we need to cover these given how expensive	Must Add- 0
IV		they are? : these are very rare conditions and	May Add- 11
	☐ Do Not Add	we have policies to limit use for the gene therapies.	Do Not Add- 0
Omlonti (omidenepag isopropyl)	☐ Must Add		Must Add- 0
opthalmic drops	⊠ May Add	None	May Add- 11
optimine drops	☐ Do Not Add		Do Not Add- 0
Lytgobi (futibatinib) tab	☐ Must Add		Must Add- 0
7.8		None	May Add- 11
	☐ Do Not Add		Do Not Add- 0
Spevigo (spesolimab-sbzo) IV	☐ Must Add		Must Add- 0
- F	⊠ May Add	None	May Add- 11
	☐ Do Not Add		Do Not Add- 0

Sotyktu (deucravacitinib) tab	☐ Must Add ☑ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 11 Do Not Add- 0
Relyvrio (sodium phenylbutyrate and taurursodiol) packet	☐ Must Add ☑ May Add ☐ Do Not Add	the rating scale. How does this compare to the other drugs?  Radicava had similar efficacy and impact on the ALS rating scale.	Must Add- 0 May Add- 11 Do Not Add- 0
Xenpozyme (olipudase alfa-rpcp) IV	☐ Must Add ☐ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 11 Do Not Add- 0

Abbreviated New Products				
Drug Name	Decision All Lines of Business (Where applicable)	Discussion	Vote Count	
Aponvie (aprepitant) IV	☐ Must Add ☐ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 11 Do Not Add- 0	
Auvelity (dextromethorphan hydrobromide, bupropion) ER tab	☐ Must Add ☑ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 11 Do Not Add- 0	
Calquence (acalabrutinib) tablet	☐ Must Add ☐ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 11 Do Not Add- 0	
Cimerli (ranibizumab-eqrn) injection	☐ Must Add ☑ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 11 Do Not Add- 0	
Daxxify (daxibotulinumtoxinA-lanm) injection	☐ Must Add ☐ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 11 Do Not Add- 0	
Furoscix (furosemide) injection	☐ Must Add ☐ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 11 Do Not Add- 0	
Hadlima (adalimumab–bwwd) SQ	☐ Must Add ☑ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 11 Do Not Add- 0	
Iheezo (chloroprocaine) ophthalmic gel	☐ Must Add ☑ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 11 Do Not Add- 0	
Juvederm Volux XC (hyaluronic acid) injectable gel	☐ Must Add ☑ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 11 Do Not Add- 0	

Kovnomep (omeprazole, sodium	☐ Must Add		Must Add- 0
	☐ May Add	None	May Add- 11
bicarbonate) susp	☐ Do Not Add	INOLIC	Do Not Add- 0
Kyzatrex (testosterone	☐ Must Add		Must Add- 0
1	☐ May Add	None	May Add- 11
undecanoate) cap	☐ Do Not Add	INOTIE	Do Not Add- 0
Midagalam 10m a/0.7ml	☐ Must Add		Must Add- 0
Midazolam 10mg/0.7ml	☐ May Add	None	May Add- 11
autoinjector	□ Do Not Add	None	Do Not Add- 0
D 1 1 ( 1' 4' 10 ( )	☐ Must Add		Must Add- 0
Pedmark (sodium thiosulfate)	☐ Must Add	Alleria	May Add- 11
injection	□ Do Not Add	None	Do Not Add- 0
Pheburane (sodium phenylbuturate)	☐ Must Add		Must Add- 0
oral pellets	May Add	None	May Add- 11
-	☐ Do Not Add		Do Not Add- 0
Rolvedon (eflapegastim-xnst)	☐ Must Add		Must Add- 0
injection	⊠ May Add	None	May Add- 11
	☐ Do Not Add		Do Not Add- 0
Stimufend (pegfilgrastim-fpgk) IV	☐ Must Add		Must Add- 0
4 6 6 16 /	May Add	None	May Add- 11
	☐ Do Not Add		Do Not Add- 0
Tadliq (tadalafil) suspension	☐ Must Add		Must Add- 0
, , ,		None	May Add- 11
	☐ Do Not Add		Do Not Add- 0
Tascenso ODT (fingolimod) tablet	☐ Must Add		Must Add- 0
		None	May Add- 11
	☐ Do Not Add		Do Not Add- 0
Terlivaz (terlipressin) injection	☐ Must Add		Must Add- 0
	May Add	None	May Add- 11
	☐ Do Not Add		Do Not Add- 0
Turalio (pexidartinib) 125 mg cap	☐ Must Add		Must Add- 0
	May Add	None	May Add- 11
	☐ Do Not Add		Do Not Add- 0
Ultomiris (eculizumab) SQ	☐ Must Add		Must Add- 0
		None	May Add- 11
	☐ Do Not Add		Do Not Add- 0
Vegzelma (bevacizumab-adcd) IV	☐ Must Add		Must Add- 0
	May Add □	None	May Add- 11
	☐ Do Not Add		Do Not Add- 0
Xofluza (baloxavir marboxil) 2%	☐ Must Add		Must Add- 0
granules for oral suspension		None	May Add- 11
	☐ Do Not Add		Do Not Add- 0

Zoryve (roflumilast) cream	☐ Must Add		Must Add- 0
, (	⊠ May Add	None	May Add- 11
	☐ Do Not Add		Do Not Add- 0

New FDA Indications				
Drug Name	Decision All Lines of Business (Where applicable)	Discussion	Vote Count	
Abrilada (adalimumab-afzb) SQ	<ul><li>☑ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0	
Amjevita (adalimumab-atto) SQ	<ul><li>☑ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0	
Benlysta (belimumab) IV	<ul><li>☑ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0	
Boostrix (tetanus, diphtheria, acellular pertussis (Tdap) vaccine	<ul><li>☑ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0	
Diacomit (stiripentol) susp	<ul><li>☒ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0	
Dupixent (dupilumab) injection	<ul><li>☑ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0	
Enhertu (fam-trastuzumab- deruxtecan-nxki) IV	No Change     □ Change	None	No Change- 11 Change- 0	
Firdapse (amifampridine) tablet	<ul><li>☑ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0	
Hadlima (adalimumab – bwwd)	<ul><li>☒ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0	
Hyrimoz (adalimumab-adaz) injection	<ul><li>☑ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0	
Imbruvica (ibrutinib) tab/cap	No Change     □ Change	None	No Change- 11 Change- 0	
Imfinzi (durvalumab) IV	<ul><li>☒ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0	
Lyumjev (insulin lispro-aabc) injection	No Change     □ Change	None	No Change- 11 Change- 0	
Mirena (levonorgestrel-releasing intrauterine system)	No Change     □ Change	None	No Change- 11 Change- 0	

Myfembree (relugolix, estradiol, and norethindrone acetate) tab	⊠ No Change □ Change	None	No Change- 11 Change- 0
Nubeqa (darolutamide) tab	<ul><li>☑ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0
Opzelura (ruxolitinib) cream	<ul><li>⋈ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0
Orkambi (ivacaftor/lumacaftor) oral granule	No Change     □ Change	None	No Change- 11 Change- 0
Oxlumo (lumasiran) SQ	<ul><li>☑ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0
Pemazyre (pemigatinib) tab	<ul><li>☑ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0
Rebinyn (coagulation factor IX [recombinant], GlycoPEGylated) IV	⊠ No Change □ Change	None	No Change- 11 Change- 0
Retevmo (selpercatinib) caps	<ul><li>☑ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0
Stelara (ustekinumab) SQ	<ul><li>☑ No Change</li><li>☐ Change</li></ul>	None	No Change- 11 Change- 0
Vemlidy (tenofovir alafenamide) tablet	No Change     □ Change	None	No Change- 11 Change- 0
Xofluza (baloxavir marboxil) tab/susp	⊠ No Change ☐ Change	None	No Change- 11 Change- 0

DURs	
	Discussion
Medicare	: What was the tramadol DUR? Andrea Keck: appeals were assessed to see why they were
PA Medicaid	denied & then overturned and found that many lacked appropriate information. Provider education was
DE Medicaid	created.

Formulary Review & Revisions					
PA Medicaid					
Drug Name Recommendation Decision Discussion Vote Count					
Omnipod Pod Pals	Add to formulary		None	Add- 11 Do Not Add-0	

Excluded specialty vitamin products	Remove from	Remove	None	Remove- 11
and vitamin mixtures	formulary	□ Do Not Remove	110110	Do Not Remove-0

Formulary Review & Revisions				
DE Medicaid				
Drug Name	Recommendation	Decision	Discussion	Vote Count
Omnipod Pod Pals Sodium phenylbutyrate 500mg tab and powder	Add to formulary		None	Add- 11 Do Not Add-0
Excluded specialty vitamin products, vitamin mixtures, and natural products	Remove from formulary	<ul><li>☒ Remove</li><li>☐ Do Not Remove</li></ul>	None	Remove- 11 Do Not Remove-0

Formulary Review & Revisions				
Medicare				
Drug Name	Recommendation	Decision	Discussion	Vote Count
Omnipod Pod Pals Caplyta 10 and 21mg Quetiapine 150mg tab Priorix Vaccine Skyrizi SQ	Add to formulary	⊠ Add □ Do Not Add	None	Add- 11 Do Not Add- 0
Clindamycin-P (clindamycin phosphate 1%) swab	Remove from formulary	<ul><li>☑ Remove</li><li>☑ Do Not Remove</li></ul>	None	Remove- 11 Do Not Remove-0

Policies			
Medicare Part D (pharmacy)			
Policy Name	New/Revision	Decision (vote is for all new and revised policies)	Discussion
None	□ New Policy     □ Policy Revision	<ul><li>☒ Approve as Written</li><li>☒ Do Not Approve as Written</li></ul>	None
Nuvigil Provigil Skyrizi Xyrem	☐ New Policy ☐ Policy Revisions	<ul><li>☑ Approve as Written</li><li>☐ Do Not Approve as Written</li></ul>	None
None	Retire	<ul><li>☑ Approve Retirement</li><li>☐ Do Not Approve Retirement</li></ul>	None
Medicare Part B (medical)			

Cimerli Skyrizi Xenpozyme	New Policy     □ Policy Revision	<ul><li>☑ Approve as Written</li><li>☐ Do Not Approve as Written</li></ul>	None	
Aralast NP Crysvita Elaprase Glassia Kalbitor Krystexxa Mepsevii Naglazyme Prolastin Remodulin Ruconest Tyvaso Ventavis Vimizim Voxzogo Xiaflex Zemaira	☐ New Policy ☑ Policy Revisions	<ul><li>☑ Approve as Written</li><li>☐ Do Not Approve as Written</li></ul>	None	
Medicare Operational Policies				
Delegate Oversight Handling Part D Drug Recalls, Discontinuations, and Shortages Opioid Management Strategy Program Oversight of PBM Parts B Versus D Medication Coverage	☐ New Policy ☐ Policy Revision	<ul><li>☑ Approve as Written</li><li>☐ Do Not Approve as Written</li></ul>	None	
None	⊠ Retire	<ul><li>☒ Approve Retirement</li><li>☐ Do Not Approve Retirement</li></ul>	None	
Policies				
PA Medicaid				
Policy Name	New/Revision	<b>Decision</b> (vote is for all new and revised policies)	Discussion	
Skysona Xenpozyme	<ul><li>☑ New Policy</li><li>☐ Policy Revision</li></ul>	<ul><li>☑ Approve as Written</li><li>☑ Do Not Approve as Written</li></ul>	None	

Aduhelm			None
Alpha-1 Proteinase Inhibitors			
Crysvita			
Enzyme Replacement Therapy, Pompe Disease			
Gattex			
Immune Globulin Products			
Isturisa			
Myalept			
Neudexta	☐ New Policy	Approve as Written	
Onpattro, Tegsedi, and Amvuttra	☐ New Folicy ☐ Policy Revisions		
Phenylketonuria Medications	Policy Revisions	☐ Do Not Approve as Written	
PAH İnjectable Agents			
Qbrexza			
Quantity Limits			
Strensig			
Sucraid			
Vyndagel and Vyndamax			
Xiaflex			
Xywav			
PA Medicaid Operational Policies			
Clinical Policy Development Process			
Direct Member Reimbursement			
Pharmacy & Therapeutics Committee			
Pharmacy Access During Disasters			
Pharmacy Auxiliary Services			
Pharmacy Benefit Setup			
Pharmacy Care Coordination with BH-MCOs	☐ New Policy	Approve as Written	None
Pharmacy Copays	□ Policy Revisions	☐ Do Not Approve as Written	THORE
Pharmacy Member Portal			
Recipient Restriction Program			
Second Level PBM Provider Pricing Dispute Resolution Process			
Specialty Pharmacy Program			
Split Fill Program	<u></u>		
Spill Fill Flogram			
Policies			
DE Medicaid			
	<u></u>	Decision	
Policy Name	New/Revision	(vote is for all new and	Discussion
		revised policies)	
Skysona	New Policy	Approve as Written	Name
Xenpozyme	☐ Policy Revision	☐ Do Not Approve as Written	None

Aduhelm Alpha-1 Proteinase Inhibitors Antihemophilia agents and blood factor products Anti-Obesity Agents CGRP Inhibitors and Serotonin (5-HT)1F Receptor Agonists Carisoprodol Chronic GI Motility Medications Cinacalcet Crysvita Cytokine and CAM Antagonists Enzyme Replacement Therapy, Pompe Disease Gattex Growth Hormone Hereditary Angioedema Agents Hyperkalemia Agents Immune Globulin Products Isturisa Krystexxa Lidoderm 5% Topical Patch Lyrica Marinol Myalept Neudexta Onpattro, Tegsedi, and Amvuttra Orral Isotretinoin Agents Oriahnn and Myfembree Phenylketonuria Medications Phosphate Binders Provigil and Nuvigil PAH Agents Qbrexza Quantity Limit and Dose Optimization Ravicti Stimulant Medications Strensiq Topical Immunomodulators Vyndaqel and Vyndamax Xiaflex Xifaxan Xywav and Xyrem	☐ New Policy ☑ Policy Revisions	Approve as Written Do Not Approve as Written	None
Vyvanse to treat Binge Eating Disorder	□ Retire	Approve Retirement	None
	Z reme	☐ Do Not Approve Retirement	None
DE Medicaid Operational Policies			
HHO Pharmacy – Health Related Social Needs Pharmacy Regulatory Reporting	<ul><li>☑ New Policy</li><li>☐ Policy Revision</li></ul>	<ul><li>☑ Approve as Written</li><li>☐ Do Not Approve as Written</li></ul>	None

November 3, 2022 P&T Committee Meeting Minutes 5:00 PM

Clinical Pharmacy Prior Authorization Process			
Continuity of Care of Pharmaceutical Services			
COVID-19 OTC At-home Test and Oral Antiviral Coverage			
Disasters			
Drug Utilization Reviews			
Formulary Management			
Inclusions, Exclusions, and Exceptions			
Medication Therapy Management			
PBM Oversight			
Pharmacy & Therapeutics Committee	□ New Policy	Approve as Written	None
Pharmacy and PCP Lock-in Program	□ Policy Revisions	☐ Do Not Approve as Written	None
Pharmacy Audit of Denial Decisions			
Pharmacy Coding Requests			
Pharmacy Denial System Controls			
Pharmacy Member Portal			
Pharmacy Provider Call Center Accessibility			
Prescription Cost Sharing			
Prior Authorization of Drugs			
Refill Too Soon Overrides			
Specialty Pharmacy Program			

	Final Discussion	
None		
Next Meeting Date: February 2, 2023		
Time Meeting Adjourned: 5:33 pm		